Cancer drug improved cognition, motor skills in small Parkinson's clinical trial
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson's disease and Lewy body dementia in a small phase I clinical trial, report researchers. In addition, the drug, nilotinib (Tasigna by Novartis), led to statistically significant and encouraging changes in toxic proteins linked to disease progression (biomarkers). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 17, 2015 Category: Science Source Type: news
Tasigna Shows Promise in Systemic Sclerosis (CME/CE)
(MedPage Today) -- Skin scores improved at 12 months, but tolerability limited by mild QTc prolongation (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - August 27, 2015 Category: Dermatology Source Type: news
Laurie Letvak
Vice President and Head of Clinical Development Policy Dr. Laurie Letvak is Vice President and Head of Clinical Development Policy at Novartis, a position she has held since June 2014.
Laurie has been with Novartis for 20 years in a variety of positions. She played a key role in the development of Gleevec® since joining the International Project Team in 2001, responsible for Global Medical Affairs. She led the development of the Medical Affairs program, which resulted in many key studies, some of which have provided the data for new indications for Gleevec ®, including Ph+ ALL and Adjuvant GIST. From 2008-2012,...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
87% Complete Remission Rate With Nilotinib in ALL87% Complete Remission Rate With Nilotinib in ALL
Low-intensity chemotherapy plus nilotinib was highly effective in older patients, and might be an alternative to stem cell transplantation. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 17, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Novartis Japan Apologizes Again for Second Side-Effects Scandal
The Japanese unit of Novartis has apologized for failing to report the side-effects of its leukemia drugs, Gleevec and Tasigna -- the second recent scandal the drugmaker has faced surrounding inappropriately-reported side-effects. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 31, 2014 Category: Pharmaceuticals Source Type: news
Nilotinib Associated With Increased Peripheral Artery Disease Rate in CML
Two studies found higher rates of peripheral artery occlusive disease in nilotinib-treated chronic myeloid leukemia patients than in imatinib-treated patients. (Source: Cancer Network)
Source: Cancer Network - May 13, 2013 Category: Cancer & Oncology Source Type: news
Nilotinib for CML Leads to Fewer Treatment-Emergent Mutations Than Imatinib
CML patients treated with nilotinib had fewer treatment-emergent BCR-ABL mutations than those treated with imatinib, and among patients who did have a mutation, those treated with nilotinib had reduced rates of progression to accelerated phase and blast phase of the disease. (Source: Cancer Network)
Source: Cancer Network - April 12, 2013 Category: Cancer & Oncology Source Type: news
CHMP recommends approval of bosutinib (Bosulif®) for CML
Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a conditional marketing authorisation for the orphan medicine bosutinib (Bosulif®) for the treatment of adults with Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. Bosutinib is a protein kinase inhibitor that acts by inhibiting the abnormal Bcr-Abl kinase that promotes CML.
The positive...
Source: NeLM - News - January 21, 2013 Category: Drugs & Pharmacology Source Type: news
Early molecular response may predict outcomes for nilotinib in CML
Branford S. J Clin Oncol. 2012;doi:10.1200/JCO.2011.40.5217. (Source: HemOncToday.com)
Source: HemOncToday.com - January 14, 2013 Category: Cancer & Oncology Source Type: news
